中药胃肠安防治进展期胃癌术后转移的临床研究

目的：观察中药胃肠安对进展期胃癌术后转移的影响。方法：采用前瞻性随机分组对照，将148例进展期胃癌根治术后患者分为胃肠安组、化疗组和胃肠安加化疗组(简称中西医组)。观察3组患者的生存率、转移率、生存质量和转移复发后带瘤生存时间。结果：胃肠安组的术后1、2、3年生存期分别为93．23％、79．34％、71．78％，中西医组分别为89．51％、69．77％、55．76％，明显高于化疗组的83．86％、59．33％、49．43％(P<0．05)；胃肠安组与中西医组比较差异无显著性。1、2、3年转移率胃肠安组分别为15．25％、28．81％、33．90％，中西医组分别为15．52％、41．38％、46．55％，但只有术后1年转移率胃肠安组及中西医组与化疗组比较，差异有显著性(P<0．05)；2、3年转移率差异无显著性，但均明显低于化疗组(分别为35．48％，45．16％，51．61％)。胃肠安组的生存质量和复发转移后的生存时间明显好于化疗组(P<0．05)。结论：中药胃肠安对胃癌术后患者的复发转移有防治作用。

Clinical Study on Post-operative Metastasis Prevention of Progressive Stage of Gastric Cancer by Weichang′an

OBJECTIVE: To observe the effect of Weichang'an (WCA, a Chinese preparation) in preventing post-operative metastasis of progressive stage of gastric cancer. METHODS: A prospective randomized, controlled study was conducted by dividing the 148 patients of progressive staged gastric cancer after radical operation into the WCA group, the chemotherapy (CT) group and the WCA + CT group, to observe the survival rate, metastasis rate, quality of life (QOF) and tumor-bearing survival time after relapse (TST) in patients. RESULTS: The 1-, 2- and 3-year survival rate after operation in the WCA + CT group was 89.51%, 69.77% and 55.76% respectively, which was significantly higher than that in the CT group (83.86%, 59.33% and 49.43%) respectively (P < 0.05), but showed insignificant difference as compared with that in the WCA group (93.23%, 79.34% and 71.78%). Only 1-year metastasis in the WCA group was 15.25%, and in the WCA + CT group was 15.52%, the two were significantly lower than that in the CT group (35.48%, P < 0.05). But the comparison of 2-year metastasis rate among the 3 groups (28.81%, 41.38% and 45.16%) and 3-year metastasis rate among them (33.90%, 46.55% and 51.61%) were insignificantly different. The QOF and TST were markedly better in the WCA group than those in the CT group. CONCLUSION: WCA has preventive effect on relapse and metastasis in post-operational gastric cancer patients.